Tests a CCR8 antibody alone and with PD-1 therapy in advanced solid tumors

Tests denikitug, alone or with anti-PD-1 therapy, in adults with advanced solid tumors.

Plain-language title generated from the registry record
Registry title: A Phase 1 Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Denikitug (GS-1811), an Afucosylated Anti-CCR8 Monoclonal Antibody, as Monotherapy and in Combination With an Anti–PD-1 Monoclonal Antibody in Adults With Advanced Solid Tumors

Key facts

Where

Edegem, Hasselt, and Leuven, BelgiumSee the 3 sites

Phase

Phase 1